Actively Recruiting
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Led by Grit Biotechnology · Updated on 2026-04-14
12
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
CONDITIONS
Official Title
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily join the study, signed informed consent form, willing and able to comply with the study protocol
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of at least 3 months
You will not qualify if you...
- Central nervous system dysfunction with clinical significance such as seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS
- Any form of primary or acquired immunodeficiency, including known HIV positive status
- Experienced myocardial infarction or unstable angina within 6 months prior to screening
- Pleural effusion requiring drainage for symptom management within 28 days prior to screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
Research Team
B
Bo Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here